Study results on Nicox compounds presented, including internally-developed pipeline candidates NCX 667, NCX 1653 and NCX 4240, as well as latanoprostene bunod results presented by licensee Bausch + Lomb

………………………………………………………………………………………….

Sophia Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the presentation of seven posters highlighting scientific data for its internally developed and partnered pipeline candidates at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting, one of the key scientific events in the ophthalmology calendar, which was held on May 1-5, 2016 in Seattle, Washington, United States.

Dr. Michael Bergamini, Chief Scientific Officer and Executive Vice President at Nicox, commented: “Beyond latanoprostene bunod and AC-170, for which New Drug Applications are under review with the U.S. Food and Drug Administration (FDA), Nicox has a pipeline of promising and unencumbered ophthalmology assets targeting significant ocular indications, including blepharitis, glaucoma and certain conjunctival disorders. At ARVO this year, in addition to latanoprostene bunod presentations by Bausch + Lomb, Nicox presented three posters on our internally-developed pipeline candidates, NCX 667, NCX 1653 and NCX 4240. These preclinical studies provide early evidence of activity and/or tolerability and reflect our continued commitments to leveraging our proprietary nitric oxide (NO)-donating platform and to creating novel therapeutics to treat ocular diseases.”

Details for the poster presentations at ARVO 2016 are as follows and abstracts have been published at the meeting website http://www.arvo.org/AM/Program/ .

Latanoprostene bunod

Title: Long-term Efficacy and Safety of Latanoprostene Bunod 0.024% for Intraocular Pressure Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension: APOLLO and LUNAR Studies
Date and time: Tuesday, May 3, 2016 from 8:30am – 10:15am PT
Presenter: Jason Vittitow, Bausch + Lomb
Session: Glaucoma clinical studies / Pharmacology
Abstract and poster board #: 3030 – A0379
Location: Exhibit/Poster Hall

Title: Efficacy of Latanoprostene Bunod 0.024% vs. Timolol Maleate 0.5% for Intraocular Pressure Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension: the LUNAR Study
Date and time: Tuesday, May 3, 2016 from 8:30am – 10:15am PT
Presenter: James Peace, United Medical Research Institute
Session: Glaucoma clinical studies / Pharmacology
Abstract and poster board #: 3035 – A0384
Location: Exhibit/Poster Hall

Title: Integrated Efficacy of Latanoprostene Bunod 0.024% vs. Timolol Maleate 0.5% for Intraocular Pressure Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension: APOLLO and LUNAR Studies
Date and time: Tuesday, May 3, 2016 from 8:30am – 10:15am PT
Presenter: Paul Kaufman, University of Wisconsin School of Medicine and Public Health
Session: Glaucoma clinical studies / Pharmacology
Abstract and poster board #: 3036 – A0385
Location: Exhibit/Poster Hall

Title: Long-term Safety and Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: the JUPITER Study
Date and time: Tuesday, May 3, 2016 from 8:30am – 10:15am PT
Presenter: Kazuhide Kawase, Gifu University Hospital
Session: Glaucoma clinical studies / Pharmacology
Abstract and poster board #: 3037 – A0386
Location: Exhibit/Poster Hall

Nicox’s internally-developed product candidates

Title: IOP-lowering effects of NCX 667 in combination with travoprost in ocular normotensive and transient hypertensive rabbits
Date and time: Tuesday, May 3, 2016 from 8:30am – 10:15am PT
Presenter: Elena Bastia, Nicox Research Institute
Session: Glaucoma clinical studies / Pharmacology
Abstract and poster board #: 3031 – A0380
Location: Exhibit/Poster Hall

Title: Intraocular pressure-lowering and ocular exposure of NCX 1653, a novel nitric oxide-donating travoprost in models of ocular hypertension and glaucoma
Date and time: Tuesday, May 3, 2016 from 8:30am – 10:15am PT
Presenter: Francesco Impagnatiello, Nicox Research Institute
Session: Glaucoma clinical studies / Pharmacology
Abstract and poster board #: 3034 – A0383
Location: Exhibit/Poster Hall

Title: Anti-viral efficiency of NCX4240 (iota-carrageenan) eye drops against Adenoviruses (AdV) causing epidemic keratoconjunctivitis (EKC)
Date and time: Wednesday, May 4, 2016 from 3:45pm – 5:30pm PT
Presenter: Brigitte Duquesroix, Nicox
Session: Inflammation
Abstract and poster board #: 5406 – B0146
Location: Exhibit/Poster Hall